After resection of pancreatic ductal adenocarcinoma, does adjuvant gemcitabine plus capecitabine improve survival compared with gemcitabine alone? [ESPAC-4]
After resection of pancreatic ductal adenocarcinoma, does adjuvant gemcitabine plus capecitabine improve survival compared with gemcitabine alone?
Absolute Effect
Median OS was 28.0 months with gemcitabine/capecitabine versus 25.5 months with gemcitabine; HR 0.82 (95% CI 0.68–0.98), P=.032. Five-year OS in long-term follow-up was approximately 28% vs 20%.
Absolute effect: Five-year OS improved by approximately 8 percentage points in long-term follow-up (about 28% vs 20%). Median OS difference was 2.5 months.
NNT: 13, based on the long-term 5-year overall survival difference of approximately 8 percentage points. This is an approximate landmark NNT because the published five-year estimates are rounded.
NNH: not quantifiable from the primary publication because overall grade 3–4 event burden was reported as counts rather than a single mutually exclusive patient-level toxicity endpoint.
Follow-up: Long-term follow-up approximately 60 months in the five-year analysis.
Clinical results and treatment burden
- Intervention: Six cycles of gemcitabine plus oral capecitabine versus six cycles of gemcitabine alone, beginning after recovery from surgery.
- Principal toxicity: Grade 3–4 adverse events were common in both arms; the combination produced more total grade 3–4 events (608 events in 226/359 patients) than gemcitabine (481 events in 196/366 patients).
- Other efficacy/recurrence findings: The survival benefit was present despite the heterogeneity of resection margin and nodal status; the combination became an important comparator for subsequent intensified adjuvant regimens.
- Quality of life: The trial was not primarily powered around QoL; treatment burden must be considered when comparing GemCap with more intensive modern regimens.
Eligibility and clinical context
732 enrolled; 730 patients included in final analysis after pancreatic ductal adenocarcinoma resection. The trial included R0/R1 resections and node-positive disease.
Limitations and maturity: Subsequent PRODIGE 24 established modified FOLFIRINOX as a more active adjuvant regimen in fit patients, so ESPAC-4 is now best understood as a major step in the evolution of postoperative systemic therapy.